Connection

Co-Authors

This is a "connection" page, showing publications co-authored by LEI HUO and ERIKA RESETKOVA.
Connection Strength

1.575
  1. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006 Oct 15; 107(8):1760-8.
    View in: PubMed
    Score: 0.285
  2. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Hum Pathol. 2021 02; 108:42-50.
    View in: PubMed
    Score: 0.189
  3. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res. 2020 06 23; 22(1):69.
    View in: PubMed
    Score: 0.184
  4. Clinical Management of Mucocele-Like Lesions of the Breast with Limited or no Epithelial Atypia on Core Biopsy: Experience from Two Institutions. Ann Surg Oncol. 2019 Oct; 26(11):3478-3488.
    View in: PubMed
    Score: 0.171
  5. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology. 2015 Aug; 67(2):245-54.
    View in: PubMed
    Score: 0.127
  6. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology. 2013 Jan; 62(2):267-74.
    View in: PubMed
    Score: 0.107
  7. The Prevalence of Sentinel Lymph Node Positivity and Implications for the Utility of Frozen Section Diagnosis Following Neoadjuvant Systemic Therapy in Patients with Clinically Node-Negative HER2-Positive or Triple-Negative Breast Cancer. Ann Surg Oncol. 2024 Oct; 31(11):7339-7346.
    View in: PubMed
    Score: 0.061
  8. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Arch Pathol Lab Med. 2024 Feb 01; 148(2):200-205.
    View in: PubMed
    Score: 0.059
  9. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat. 2024 Jan; 203(1):73-83.
    View in: PubMed
    Score: 0.058
  10. Metastatic nonhematopoietic neoplasms to the breast: a study of 238 cases. Hum Pathol. 2022 07; 125:59-67.
    View in: PubMed
    Score: 0.052
  11. Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall. Hum Pathol. 2022 07; 125:35-47.
    View in: PubMed
    Score: 0.052
  12. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol. 2022 07; 125:97-107.
    View in: PubMed
    Score: 0.052
  13. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol. 2022 03; 121:73-80.
    View in: PubMed
    Score: 0.051
  14. Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 2015 Apr; 22(4):1111-7.
    View in: PubMed
    Score: 0.031
  15. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology. 2011 Jul; 59(1):106-15.
    View in: PubMed
    Score: 0.025
  16. Imaging features of micropapillary DCIS: correlation with clinical and histopathological findings. Acad Radiol. 2011 Jul; 18(7):797-803.
    View in: PubMed
    Score: 0.024
  17. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011 Aug; 42(8):1169-77.
    View in: PubMed
    Score: 0.024
  18. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.